Publicly funded assisted human reproduction (AHR) has been live in Ireland since 2023. Fertility treatment that was once entirely private is now partially funded through the HSE and delivered through the public fertility pathway.
During this same period, fertility legislation has been enacted and the Assisted Human Reproduction Regulatory Authority (AHRRA) has been formally established.
However, while funding is live and treatment is being delivered, system-level outcome regulation has not yet been embedded. In particular, live birth is not measured as a tracked outcome across the publicly funded fertility pathway.
How publicly funded fertility care currently operates
The State allocates approximately €30 million annually to Ireland’s public fertility Model of Care, as defined by the HSE and the Department of Health.
This funding supports a multi-stage pathway. Patients enter through primary care, progress to HSE fertility hubs for assessment and management, and for a subset of patients, are referred onward for Assisted Human Reproduction (AHR).
AHR treatment — including IUI, IVF, and ICSI — is publicly funded but delivered by private fertility clinics under HSE funding arrangements.
According to the HSE’s most recently published figures, approximately one third of patients referred through the public fertility pathway progress to AHR.
The remaining majority complete the pathway without achieving a live birth. HSE-published data indicates that approximately 70% of patients entering the publicly funded fertility pathway do not achieve a live birth, regardless of whether they progress to AHR
Regulation: established in law, limited in operation
The Health (Assisted Human Reproduction) Act 2024 provides the statutory framework for fertility regulation in Ireland. Under this Act, the Assisted Human Reproduction Regulatory Authority (AHRRA) has been formally established.
The Authority is intended to license fertility clinics, set enforceable standards of practice, oversee compliance, and regulate donor-assisted conception and surrogacy.
However, while the Authority exists in statute, system-level regulatory functions are not yet fully operational across publicly funded fertility care. In particular:
- fertility clinics delivering publicly funded AHR are not yet operating under a mature, inspection-led regulatory regime
- there is no established system of routine, regulator-verified clinic inspections specific to fertility care
- there is no mandatory, system-wide public reporting of outcomes across the publicly funded fertility pathway
Publicly funded fertility treatment is therefore being delivered through outsourced private providers without an established framework for system-level accountability.
Live birth: the outcome patients are seeking
Patients enter the HSE fertility pathway seeking a live birth. That outcome — not access, referral, or treatment initiation — is the measure that matters to those using the system.
At present, live birth is not tracked as a system-level outcome across the publicly funded fertility pathway, including outsourced AHR provision.
This means that neither patients nor the State can evaluate whether publicly funded fertility care is delivering the outcome it is designed to achieve.
Without live birth as a tracked system outcome:
- patients cannot assess the likelihood of success when entering the pathway
- performance cannot be compared across providers or stages of care
- improvement cannot be measured over time
- accountability remains diffuse
This is not a judgement on individual clinicians or clinics. It is a structural observation about what the system measures — and what it does not.
Why outcome measurement matters in a funded system
Public funding creates obligations beyond eligibility criteria. It requires the ability to assess whether the system is functioning effectively.
In the absence of outcome measurement, patients are asked to enter the publicly funded fertility pathway without visibility on the likelihood of achieving a live birth.
At a policy level, decisions about access and funding are therefore made without reference to verified outcome data.
How the UK system differs
The UK offers a useful comparison.
Fertility clinics in the UK are regulated by the Human Fertilisation and Embryology Authority (HFEA), an independent statutory regulator with operational oversight.
The HFEA licenses clinics, conducts inspections, and publishes verified clinic-level data, including treatment volumes, pregnancy rates, live birth outcomes, and inspection findings.
This data is publicly accessible and updated on a routine basis.
The difference between the Irish and UK systems is not funding alone. It is the presence of operational regulation, outcome transparency, and system-wide visibility.
Final reflection
Publicly funded fertility care represents an important shift in Irish healthcare.
That does not make scrutiny premature. It makes it necessary.
Live birth is the outcome patients enter the HSE fertility pathway seeking.
It must also be the outcome the system is designed to measure.
In the absence of system-level live birth measurement, evidence-based preparation becomes the primary mechanism through which outcomes can still be positively influenced. Preparation is not about adapting to system constraints. It is about shaping the biological conditions that determine whether fertility treatment has the capacity to succeed — including metabolic health, inflammatory load, nutrient sufficiency, sperm quality, and cycle function — before eligibility thresholds, waiting times, and treatment decisions narrow what is possible. In a system that emphasises assessment and triage rather than preparation for success, this phase becomes the primary opportunity for influencing outcome.
